Skip to content
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
    • Cholangio Challengers
      • Cholangio Challengers For Supporters
      • Cholangio Challengers For Patients
    • Light Australia Green
  • How We Win
  • About Us
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Histotripsy Australia
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
    • Become A Mentor
    • Become a Volunteer
    • Become an Ambassador
    • Volunteer Positions Available0431 180 783
Latest News:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
    • Cholangio Challengers
      • Cholangio Challengers For Supporters
      • Cholangio Challengers For Patients
    • Light Australia Green
  • How We Win
  • About Us
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Histotripsy Australia
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
    • Become A Mentor
    • Become a Volunteer
    • Become an Ambassador
    • Volunteer Positions Available0431 180 783
Latest:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Patients
Donate
Clinicians
Tim Greten, NIH 2018- Cholangiocarcinoma and Immunotherapy

Tim Greten, NIH 2018- Cholangiocarcinoma and Immunotherapy

Search more video options in TAGS

Tags

Adoptive Sell Therapy ARID1A Australia BAP1 Bile Gone Bad BRCA1/2 Car-T Cells Chemotherapy Clinical Trial dmmr durvalumab EGFR FGFR2 Gem/Cis Graeme Holmes HER2 amplification How IDH1 immunotherapy Intrahepatic Keytruda MSI-H Mutations olaparib Oncologists Organisations patient Patient Success PD-1 Checkpoint inhibitors PD-L1 Pembrolizumab Steve Holmes Surgery Testimonials TP53 treatment Trial Patient USA Videos-About + Options videos-How Videos-Immuno Videos-Patients Videos-Surgery Videos-Trials whipple

Shared Information improves and Galvanises our Outcomes
What do you think about this video ? can you recommend a video? We welcome your comments?


Steve2024-10-11T16:13:33+10:00

Share this Story

FacebookXLinkedInWhatsAppEmail

About the Author: Steve

Founder & CEO at Cholangiocarcinoma Foundation Australia | Late-Stage, Stage 4 CCA Survivor | Passionate Road Cyclist | Personal page for details https://steveholmes.net.au/

Related Posts

Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
Michael Flannery: Life Goes On: My Journey with Cholangiocarcinoma
Steve Holmes Patient Survivor: 14000 kilometre Cycling Circumnavigation of Australia
The Checkpoint Pathway: Ipilimumab and Keytruda immunotherapy combination
0 0 votes
Article Rating
Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments
See All

Need Help Now

Connect with Steve
+61 415 153 522
steve@cholangio.org

Connect with Claire
+61 431 180 783
claire@cholangio.org

Connect With Us

Patient-led. Built by survivors. Powered by action.

Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC). Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office. Donations over $2 or more are tax-deductible. ABN: 93 665 038 102

© 2025 | All Rights Reserved | Cholangiocarcinoma Foundation Australia

Page load link
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply
Go to Top